In obese mice, 8 weeks of treadmill running (300 min/week) and the ACE inhibitor enalapril (10 mg/kg/day) each cut weight gain, lowered liver oxidative stress, dampened renin-angiotensin system overactivation, and reduced pancreatic islet hypertrophy caused by a high-fat diet. The divergence came in inflammation: enalapril-treated livers kept elevated IL-6, NFκB, TGF-β and CD11c, while trained animals returned to chow-fed levels. Enalapril-only mice also kept enlarged islets.
The evidence comes entirely from mice, so it cannot be applied to people directly. Still, the pattern fits a broader picture. Exercise acts on many pathways at once, including muscle-derived myokines, improved insulin sensitivity and reduced visceral fat, whereas RAS blockade targets one axis. That could explain why enalapril fixed oxidative stress yet left the inflammatory and profibrotic signals (TGF-β in particular) running. Persistent TGF-β matters because it drives progression from simple steatosis toward fibrosis. In humans, exercise is already a first-line recommendation for MASLD, and this work supports its anti-inflammatory edge over a common blood-pressure drug. It does not argue against ACE inhibitors for hypertension, which have their own proven benefits. Caveats include male mice only, a short intervention, protein-level snapshots without functional or fibrosis outcomes, and no test of whether the combination adds benefit. An incremental, confirmatory mechanistic study from the same group, useful mainly for reinforcing exercise as the more complete liver therapy.